Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine

Journal of Clinical Virology

Volumn 41, Issue 4, 2008, Pages 310-313

  Sungkanuparph, Somnuek ^a   Manosuthi, Weerawat ^b   Kiertiburanakul, Sasisopin ^a   Saekang, Nipa ^a   Pairoj, Wantanit ^a   Chantratita, Wasun ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MINISTRY OF PUBLIC HEALTH   (Thailand)

Author keywords

HIV; K65R mutations; Lamivudine; Nevirapine; Stavudine

Indexed keywords

LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; FEMALE; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT FAILURE; VIRUS RESISTANCE;

ADULT; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MUTATION, MISSENSE; NEVIRAPINE; PREVALENCE; RISK FACTORS; RNA, VIRAL; STAVUDINE; VIRAL LOAD;

EID: 40849114291     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2007.12.015     Document Type: Article

References (17)

1. Cohen J. Thailand's do-it-yourself therapy. Science 301 (2003) 1662
2. Gallant J.E., and Deresinski S. Tenofovir disoproxil fumarate. Clin Infect Dis 37 (2003) 944-950
3. Gallant J.E., Staszewski S., Pozniak A.L., DeJesus E., Suleiman J.M., Miller M.D., et al., 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292 (2004) 191-201
4. Gallant J.E. Antiretroviral drug resistance and resistance testing. Top HIV Med 13 (2006) 138-142
5. Garcia-Lerma J.G., MacInnes H., Bennett D., Reid P., Nidtha S., Weinstock H., et al. A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation. J Virol 77 (2003) 5685-5693
6. Johnson V.A., Brun-Vezinet F., Clotet B., Kuritzkes D.R., Pillay D., and Schapiro J.M. Update of the drug resistance mutations in HIV-1: fall 2006. Top HIV Med 14 (2006) 125-130
7. Jongwutiwes U., Kiertiburanakul S., and Sungkanuparph S. Impact of antiretroviral therapy on the relapse of cryptococcosis and survival of HIV-infected patients with cryptococcal infection. Curr HIV Res 5 (2007) 355-360
8. Kuritzkes D.R. Preventing and managing antiretroviral drug resistance. AIDS Patient Care STDs 18 (2004) 259-273
9. Manosuthi W., Chottanapand S., Thongyen S., Chaovavanich A., and Sungkanuparph S. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr 43 (2006) 42-46
10. Margot N.A., Lu B., Cheng A., Miller M.D., and Study 903 Team. Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903. HIV Med 7 (2006) 442-450
11. Montaner J.S., Reiss P., Cooper D., Vella S., Harris M., Conway B., et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial. Italy, The Netherlands, Canada and Australia study. JAMA 279 (1998) 930-937
12. Spira S., Wainberg M.A., Loemba H., Turner D., and Brenner B.G. Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother 51 (2003) 229-240
13. Sungkanuparph S., Manosuthi W., Kiertiburanakul S., Piyavong B., Chumpathat N., and Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 44 (2007) 447-452
14. Trotta M.P., Bonfigli S., Ceccherini-Silberstein F., Bellagamba R., D'Arrigo R., Soldani F., et al. Clinical and genotypic correlates of mutation K65R in HIV-infected patients failing regimens not including tenofovir. J Med Virol 78 (2006) 535-541
15. White K.L., Margot N.A., Wrin T., Petropoulos C.J., Miller M.D., and Naeger L.K. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrob Agents Chemother 46 (2002) 3437-3446
16. Winston A., Mandalia S., Pillay D., Gazzard B., and Pozniak A. The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients. Aids 16 (2002) 2087-2089
17. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendation for a public health approach, 2006 revision. World Health Organization, August 7, 2006.